Sidoti Csr Brokers Decrease Earnings Estimates for USNA

Key Points

• Sidoti Csr has decreased its earnings estimate for USANA Health Sciences for Q3 2026 from $0.85 to $0.70 per share.
• USANA Health Sciences reported $0.56 earnings per share for the latest quarter, with a market cap of $369.42 million.
• Several analysts have downgraded USANA's ratings, with Wall Street Zen changing from "buy" to "hold" and Zacks Research lowering their rating to "hold" as well.

USANA Health Sciences, Inc. (NYSE:USNA - Free Report) - Equities researchers at Sidoti Csr cut their Q3 2026 earnings per share estimates for USANA Health Sciences in a report issued on Friday, October 10th. Sidoti Csr analyst A. Lebiedzinski now anticipates that the company will post earnings of $0.70 per share for the quarter, down from their prior estimate of $0.85. The consensus estimate for USANA Health Sciences' current full-year earnings is $2.45 per share.

USANA Health Sciences (NYSE:USNA - Get Free Report) last released its earnings results on Thursday, October 9th. The company reported $0.56 earnings per share (EPS) for the quarter. The business had revenue of $200.22 million for the quarter. USANA Health Sciences had a return on equity of 9.48% and a net margin of 3.79%. USANA Health Sciences has set its Q3 2025 guidance at -0.150--0.150 EPS.

USNA has been the topic of a number of other research reports. Wall Street Zen lowered USANA Health Sciences from a "buy" rating to a "hold" rating in a report on Saturday. Zacks Research lowered USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a report on Monday, September 22nd. Finally, Weiss Ratings reaffirmed a "sell (d+)" rating on shares of USANA Health Sciences in a report on Wednesday, October 8th. Three investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Reduce" and a consensus target price of $36.00.

USANA Health Sciences Trading Down 22.9%

NYSE:USNA opened at $20.22 on Monday. The firm has a market cap of $369.42 million, a P/E ratio of 11.23, a PEG ratio of 0.64 and a beta of 0.61. The stock's 50 day simple moving average is $29.63 and its 200-day simple moving average is $29.31. USANA Health Sciences has a 12-month low of $20.10 and a 12-month high of $41.83.

Institutional Trading of USANA Health Sciences

Institutional investors have recently bought and sold shares of the company. PNC Financial Services Group Inc. boosted its position in USANA Health Sciences by 339.6% during the first quarter. PNC Financial Services Group Inc. now owns 998 shares of the company's stock worth $27,000 after purchasing an additional 771 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in USANA Health Sciences by 382.5% during the second quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company's stock worth $73,000 after purchasing an additional 1,901 shares in the last quarter. CWM LLC boosted its position in USANA Health Sciences by 109.7% during the second quarter. CWM LLC now owns 2,762 shares of the company's stock worth $84,000 after purchasing an additional 1,445 shares in the last quarter. AlphaQuest LLC boosted its position in USANA Health Sciences by 300.9% during the first quarter. AlphaQuest LLC now owns 3,412 shares of the company's stock worth $92,000 after purchasing an additional 2,561 shares in the last quarter. Finally, Quantbot Technologies LP boosted its position in USANA Health Sciences by 19.5% during the second quarter. Quantbot Technologies LP now owns 3,957 shares of the company's stock worth $121,000 after purchasing an additional 646 shares in the last quarter. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other USANA Health Sciences news, insider David Mulham Mulham sold 3,515 shares of the business's stock in a transaction on Wednesday, July 30th. The stock was sold at an average price of $30.26, for a total transaction of $106,363.90. Following the sale, the insider directly owned 9,260 shares in the company, valued at approximately $280,207.60. The trade was a 27.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gilbert A. Fuller sold 1,058 shares of the business's stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $29.10, for a total value of $30,787.80. The disclosure for this sale can be found here. 0.63% of the stock is currently owned by insiders.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.